Export

EN
FR
Efavirenz + emtricitabine + tenofovir
Essential medicine status
Section:
6. Anti-infective medicines 6.4. Antiviral medicines 6.4.2. Antiretrovirals 6.4.2.5. Fixed-dose combinations of antiretrovirals
ATC codes: J05AR06
Indication
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified ICD11 code: 1C62.Z
INN
Efavirenz + emtricitabine + tenofovir
Medicine type
Chemical agent
List type
Core
Formulations
Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
EML status history
First added in 2007 (TRS 946)
Changed in 2021 (TRS 1035)
Sex
All
Age
Adolescents and adults
Therapeutic alternatives
efavirenz + lamivudine + tenofovir (ATC codes: J05AR11)
Patent information
Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Wikipedia
Efavirenz + emtricitabine + tenofovir
DrugBank
Efavirenz ,
Emtricitabine ,
Tenofovir disoproxil
Summary of evidence and Expert Committee recommendations
Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified a as therapeutic alternative for the emtricitabine component under the square box listing for efavirenz + emtricitabine + tenofovir on the EML.